Abstract:N-Acetylaspartate (NAA) is the second most abundant organic metabolite in the brain, but its physiological significance remains enigmatic. Toxic NAA accumulation appears to be the key factor for neurological decline in Canavan disease-a fatal neurometabolic disorder caused by deficiency in the NAA-degrading enzyme aspartoacylase. To date clinical outcome of gene replacement therapy for this spongiform leukodystrophy has not met expectations. To identify the target tissue and cells for maximum anticipated treatment benefit, we employed comprehensive phenotyping of novel mouse models to assess cell type-specific consequences of NAA depletion or elevation. We show that NAA-deficiency causes neurological deficits affecting unconscious defensive reactions aimed at protecting the body from external threat. This finding suggests, while NAA reduction is pivotal to treat Canavan disease, abrogating NAA synthesis should be avoided. At the other end of the spectrum, while predicting pathological severity in Canavan disease mice, increased brain NAA levels are not neurotoxic per se. In fact, in transgenic mice overexpressing the NAA synthesising enzyme Nat8l in neurons, supra-physiological NAA levels were uncoupled from neurological deficits. In contrast, elimination of aspartoacylase expression exclusively in oligodendrocytes elicited Canavan disease like pathology. Although conditional aspartoacylase deletion in oligodendrocytes abolished expression in the entire CNS, the remaining aspartoacylase in peripheral organs was sufficient to lower NAA levels, delay disease onset and ameliorate histopathology. However, comparable endpoints of the conditional and complete aspartoacylase knockout indicate that optimal Canavan disease gene replacement therapies should restore aspartoacylase expression in oligodendrocytes. On the basis of these findings we executed an ASPA gene replacement therapy targeting oligodendrocytes in Canavan disease mice resulting in reversal of pre-existing CNS pathology and lasting neurological benefits. This finding signifies the first successful post-symptomatic treatment of a white matter disorder using an adeno-associated virus vector tailored towards oligodendroglial-restricted transgene expression.

Therapeutic development for Canavan disease using patient iPSCs introduced with the wild-type ASPA gene

Cell‐Based Therapy for Canavan Disease Using Human iPSC‐Derived NPCs and OPCs

Non-genetic therapeutic approaches to Canavan disease

Developing Hypoimmunogenic Human iPSC‐Derived Oligodendrocyte Progenitor Cells as an Off‐The‐Shelf Cell Therapy for Myelin Disorders

The pathogenesis of, and pharmacological treatment for, Canavan disease

Human induced pluripotent stem cell line (SDQLCHi064-A) derived from a patient with Canavan disease carrying c.556_559dup GTTC and c.919delA mutations in the ASPA gene

Dual-function AAV gene therapy reverses late-stage Canavan disease pathology in mice

Astroglial conditional Slc13a3 knockout is therapeutic in murine Canavan leukodystrophy

Evolutionarily conserved chaperone-mediated proteasomal degradation of a disease-linked aspartoacylase variant

Uncoupling N-acetylaspartate from brain pathology: implications for Canavan disease gene therapy

Generation of Human-Induced Pluripotent Stem Cells to Model Spinocerebellar Ataxia Type 2 in Vitro

A single intravenous rAAV injection as late as P20 achieves efficacious and sustained CNS Gene therapy in Canavan mice

Cellular and molecular mechanisms of aspartoacylase and its role in Canavan disease

Patient-specific Ipsc-Derived Cardiomyocytes Reveal Aberrant Activation of Wnt/β-catenin Signaling in SCN5A-related Brugada Syndrome

Adeno-associated virus-mediated gene therapy in a patient with Canavan disease using dual routes of administration and immune modulation

Clinically Distinct Phenotypes of Canavan Disease Correlate with Residual Aspartoacylase Enzyme Activity

Canavan disease: Clinical features and recent advances in research

Long-term follow-up after gene therapy for canavan disease

Canavan Disease: Studies on the Knockout Mouse

Canavan Disease as a Model for Gene Therapy-Mediated Myelin Repair

Clinical and Aspartoacylase Gene Mutation Analysis of Canavan Disease in a Child